This Project Grant award, with federal grant ID R01DK136805, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The $305,093 award aims to develop innovative approaches for high-subzero cryopreservation of organs, with a focus on preserving liver tissue for transplantation. The 4-year project, with a completion date of April 30, 2028, will involve: Developing an...
This Project Grant award of $857,925 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project aims to advance the understanding of the role of autophagy, an intracellular degradation process, in the activation of hepatic stellate cells (HSCs) and the development of liver fibrosis in chronic liver diseases such as viral hepatitis and fatty liver disease. The research will employ novel...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,529,805.00 to the University of Pittsburgh to conduct research on strategies to enhance regulatory myeloid cell function and improve renal transplant survival in non-human primates. The research aims to test three innovative approaches: 1) using an agonistic antibody against the LILRB3 receptor to extend...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), totals $2,913,004.00 and will be implemented from June 1, 2024 to April 30, 2029. The award supports research to identify the mechanisms by which Programmed Death Ligand 1 (PD-L1) reverse or intracellular signaling acts as an immune regulator in the liver during acute infection, chronic infection, and chronic disease. The...
This federal Project Grant award, valued at $748,049.00 and granted by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to perform a multi-center validation and biological assessment of a novel pre-transplant biomarker panel to predict mortality risk in liver transplant recipients. The principal investigator is Rutgers, The State University of New Jersey, which will lead...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the Allergy and Infectious Diseases Research (CFDA 93.855) program, provides $1,286,273 to The Trustees of Columbia University in the City of New York for preclinical studies on strategies to induce liver transplant tolerance. The key objectives are to: 1) Test the ability of BCL-2 inhibitors to promote durable chimerism and reduce induction regimen toxicity for simultaneous bone marrow and...
The federal Project Grant award of $451,292.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to uncover neuronal mechanisms regulating metabolic adaptations to bacterial infections, with a focus on the brain-liver axis. The primary goals are to: 1) identify neurocircuits in the hypothalamus that monitor circulating lipoproteins and trigger counterregulatory responses during infections, and 2)...
This federal Project Grant award, in the amount of $2,454,406.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to investigate the role of the enzyme carbonic anhydrase 4 (CAR4) in regulating the activation and functions of alveolar macrophages, which are critical for the immune response to parasitic helminth infections. Specifically, the research aims to:...
This $131,474 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855) supports research to identify new drug targets against drug-tolerant strains of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The research focuses on studying how mutations in the glycerol kinase (glpK) gene impact MTB's lipid metabolism and drug tolerance, both in vitro under...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $611,129 to the Terasaki Institute for Biomedical Innovation to develop and validate a multi-organ-on-a-chip (MOC) platform. The MOC platform will consist of a vascularized liver-on-a-chip (VLOC) and a vascularized heart-on-a-chip (VHOC) integrated with a microfluidic electrochemical biosensor system. This platform...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $866,290 to Rutgers, The State University of New Jersey to characterize the molecular pathways by which hypothermic oxygenated machine perfusion (HMP-O2) mitigates preservation injury in liver transplantation. The research aims to: 1) define the protective pathways activated by HMP-O2 compared to static cold storage and 2) identify target biomarkers for organ monitoring and future therapeutic optimization of allograft function. The project leverages Rutgers' expertise in liver transplantation and machine perfusion technologies to advance the understanding of how HMP-O2 improves early allograft function and reduces post-operative complications. The award period is from June 2024 to April 2026.